Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors

V. W. Pike, M. P. Law, S. Osman, R. J. Davenport, O. Rimoldi, D. Giardinà, P. G. Camici

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Changes in the numbers of human cardiac adrenoceptors (ARs) are associated with various diseases, such as myocardial ischemia, congestive heart failure, cardiomyopathy and hypertension. There is a clear need for capability to assess human cardiac ARs directly in vivo. Positron emission tomography (PET) is an imaging technique that provides this possibility, if effective radioligands can be developed for the targeted ARs. Here, the status of myocardial AR radioligand development for PET is described. Currently, there exist effective radioligands for imaging β-ARs in human myocardium. One of these, [11C](S)-CGP 12177, is applied extensively to clinical research with PET, sometimes with other tracers of other aspects of the noradrenalin system. Alternative radioligands are in development for β-ARs, including β1-selective radioligands. A promising radioligand for imaging myocardial α1-ARs, [11C]GB67, is now being evaluated in human PET experiments. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)191-200
Number of pages10
JournalPharmaceutica Acta Helvetiae
Volume74
Issue number2-3
DOIs
Publication statusPublished - Mar 2000

Fingerprint

Positron-Emission Tomography
Adrenergic Receptors
Cardiomyopathies
Myocardial Ischemia
Myocardium
Norepinephrine
Heart Failure
Hypertension
Research

Keywords

  • Adrenoceptors
  • Carbon-11
  • Fluorine-18
  • Heart
  • Imaging
  • Positron emission tomography (PET)
  • Radioligands

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors. / Pike, V. W.; Law, M. P.; Osman, S.; Davenport, R. J.; Rimoldi, O.; Giardinà, D.; Camici, P. G.

In: Pharmaceutica Acta Helvetiae, Vol. 74, No. 2-3, 03.2000, p. 191-200.

Research output: Contribution to journalArticle

Pike, V. W. ; Law, M. P. ; Osman, S. ; Davenport, R. J. ; Rimoldi, O. ; Giardinà, D. ; Camici, P. G. / Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors. In: Pharmaceutica Acta Helvetiae. 2000 ; Vol. 74, No. 2-3. pp. 191-200.
@article{d447bfef678f4a6cbec7f3ad8384b494,
title = "Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors",
abstract = "Changes in the numbers of human cardiac adrenoceptors (ARs) are associated with various diseases, such as myocardial ischemia, congestive heart failure, cardiomyopathy and hypertension. There is a clear need for capability to assess human cardiac ARs directly in vivo. Positron emission tomography (PET) is an imaging technique that provides this possibility, if effective radioligands can be developed for the targeted ARs. Here, the status of myocardial AR radioligand development for PET is described. Currently, there exist effective radioligands for imaging β-ARs in human myocardium. One of these, [11C](S)-CGP 12177, is applied extensively to clinical research with PET, sometimes with other tracers of other aspects of the noradrenalin system. Alternative radioligands are in development for β-ARs, including β1-selective radioligands. A promising radioligand for imaging myocardial α1-ARs, [11C]GB67, is now being evaluated in human PET experiments. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Adrenoceptors, Carbon-11, Fluorine-18, Heart, Imaging, Positron emission tomography (PET), Radioligands",
author = "Pike, {V. W.} and Law, {M. P.} and S. Osman and Davenport, {R. J.} and O. Rimoldi and D. Giardin{\`a} and Camici, {P. G.}",
year = "2000",
month = "3",
doi = "10.1016/S0031-6865(99)00032-1",
language = "English",
volume = "74",
pages = "191--200",
journal = "Pharmaceutica Acta Helvetiae",
issn = "0031-6865",
publisher = "Elsevier BV",
number = "2-3",

}

TY - JOUR

T1 - Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors

AU - Pike, V. W.

AU - Law, M. P.

AU - Osman, S.

AU - Davenport, R. J.

AU - Rimoldi, O.

AU - Giardinà, D.

AU - Camici, P. G.

PY - 2000/3

Y1 - 2000/3

N2 - Changes in the numbers of human cardiac adrenoceptors (ARs) are associated with various diseases, such as myocardial ischemia, congestive heart failure, cardiomyopathy and hypertension. There is a clear need for capability to assess human cardiac ARs directly in vivo. Positron emission tomography (PET) is an imaging technique that provides this possibility, if effective radioligands can be developed for the targeted ARs. Here, the status of myocardial AR radioligand development for PET is described. Currently, there exist effective radioligands for imaging β-ARs in human myocardium. One of these, [11C](S)-CGP 12177, is applied extensively to clinical research with PET, sometimes with other tracers of other aspects of the noradrenalin system. Alternative radioligands are in development for β-ARs, including β1-selective radioligands. A promising radioligand for imaging myocardial α1-ARs, [11C]GB67, is now being evaluated in human PET experiments. Copyright (C) 2000 Elsevier Science B.V.

AB - Changes in the numbers of human cardiac adrenoceptors (ARs) are associated with various diseases, such as myocardial ischemia, congestive heart failure, cardiomyopathy and hypertension. There is a clear need for capability to assess human cardiac ARs directly in vivo. Positron emission tomography (PET) is an imaging technique that provides this possibility, if effective radioligands can be developed for the targeted ARs. Here, the status of myocardial AR radioligand development for PET is described. Currently, there exist effective radioligands for imaging β-ARs in human myocardium. One of these, [11C](S)-CGP 12177, is applied extensively to clinical research with PET, sometimes with other tracers of other aspects of the noradrenalin system. Alternative radioligands are in development for β-ARs, including β1-selective radioligands. A promising radioligand for imaging myocardial α1-ARs, [11C]GB67, is now being evaluated in human PET experiments. Copyright (C) 2000 Elsevier Science B.V.

KW - Adrenoceptors

KW - Carbon-11

KW - Fluorine-18

KW - Heart

KW - Imaging

KW - Positron emission tomography (PET)

KW - Radioligands

UR - http://www.scopus.com/inward/record.url?scp=0034126166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034126166&partnerID=8YFLogxK

U2 - 10.1016/S0031-6865(99)00032-1

DO - 10.1016/S0031-6865(99)00032-1

M3 - Article

VL - 74

SP - 191

EP - 200

JO - Pharmaceutica Acta Helvetiae

JF - Pharmaceutica Acta Helvetiae

SN - 0031-6865

IS - 2-3

ER -